Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $3.7 million.

  • Inhibikase Therapeutics' Accumulated Expenses rose 6916.94% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 6916.94%. This contributed to the annual value of $2.7 million for FY2024, which is 1858.78% up from last year.
  • As of Q3 2025, Inhibikase Therapeutics' Accumulated Expenses stood at $3.7 million, which was up 6916.94% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Inhibikase Therapeutics' Accumulated Expenses ranged from a high of $3.7 million in Q3 2025 and a low of $627399.0 during Q1 2021
  • Moreover, its 5-year median value for Accumulated Expenses was $2.3 million (2022), whereas its average is $2.4 million.
  • In the last 5 years, Inhibikase Therapeutics' Accumulated Expenses soared by 46965.36% in 2022 and then crashed by 5640.12% in 2023.
  • Inhibikase Therapeutics' Accumulated Expenses (Quarter) stood at $2.7 million in 2021, then fell by 11.68% to $2.4 million in 2022, then dropped by 5.77% to $2.3 million in 2023, then increased by 18.59% to $2.7 million in 2024, then soared by 36.43% to $3.7 million in 2025.
  • Its Accumulated Expenses was $3.7 million in Q3 2025, compared to $3.1 million in Q2 2025 and $3.5 million in Q1 2025.